RecruitingPhase 2Phase 3NCT05878951

Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms

A Multicenter Randomized Controlled Trial Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms


Sponsor

Northwestern University

Enrollment

66 participants

Start Date

Jul 13, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The objective of our multi-center randomized single-blind study is to examine the safety and effect of intra-detrusor OnabotulinumtoxinA injections at the time of holium laser enucleation of the prostate (HoLEP) in men with overactive bladder symptoms with and without urge incontinence.


Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called OnabotulinumtoxinA for people with overactive bladder, overactive bladder syndrome, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years to 89 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOnabotulinumtoxinA

Intra-detrusor OnabotulinumtoxinA is commonly known as botox


Locations(1)

Northwestern Medicine

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05878951


Related Trials